Burgundy Asset Management Ltd. lifted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 1.0% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,640,379 shares of the company’s stock after buying an additional 16,476 shares during the quarter. Burgundy Asset Management Ltd. owned 1.28% of Henry Schein worth $105,148,000 as of its most recent filing with the SEC.
Other hedge funds have also modified their holdings of the company. Swedbank AB acquired a new stake in Henry Schein in the first quarter valued at approximately $215,998,000. Norges Bank purchased a new position in shares of Henry Schein during the 4th quarter valued at approximately $111,715,000. Thompson Siegel & Walmsley LLC acquired a new stake in shares of Henry Schein during the second quarter worth approximately $46,683,000. Nuance Investments LLC increased its stake in shares of Henry Schein by 28.5% in the first quarter. Nuance Investments LLC now owns 1,755,190 shares of the company’s stock worth $132,552,000 after buying an additional 388,843 shares during the last quarter. Finally, Fiduciary Management Inc. WI increased its stake in shares of Henry Schein by 17.1% in the fourth quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock worth $172,947,000 after buying an additional 333,855 shares during the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the sale, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.14% of the stock is currently owned by insiders.
Henry Schein Stock Performance
Henry Schein (NASDAQ:HSIC – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The firm had revenue of $3.10 billion during the quarter, compared to analyst estimates of $3.27 billion. During the same period in the previous year, the business posted $1.31 EPS. Henry Schein’s revenue was up .0% on a year-over-year basis. As a group, equities analysts anticipate that Henry Schein, Inc. will post 4.75 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research analysts have weighed in on the stock. Evercore ISI decreased their price objective on shares of Henry Schein from $72.00 to $70.00 and set an “in-line” rating for the company in a report on Wednesday, August 7th. UBS Group lowered their price objective on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. reduced their target price on Henry Schein from $88.00 to $80.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Piper Sandler reiterated an “overweight” rating and issued a $86.00 target price on shares of Henry Schein in a research report on Friday, June 21st. Finally, Robert W. Baird dropped their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $77.10.
Check Out Our Latest Research Report on HSIC
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Recommended Stories
- Five stocks we like better than Henry Schein
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Viking Therapeutics Is Having a Year to Remember: Time to Buy?
- What is the FTSE 100 index?
- Leverage Proven Stock Factors With These Top 3 Smart Beta ETFs
- How is Compound Interest Calculated?
- Spread Your Bets: Winning the AI Race With Energy ETFs
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.